24/7 Emergency & General Advisory
🚨 24/7 Medical Emergency
Non-Emergency Advisory
10:00 AM – 6:00 PM, Mon–Sat
For appointments & general queries.
Join our healthcare community
Stay updated with our latest healthcare news and your appointments.
A major new study has found that certain chronic blood cancers carry detectable genetic warning signs years before a patient's condition visibly worsens. Researchers at the Wellcome Sanger Institute tracked patients with myeloproliferative neoplasms, a group of rare blood cancers, for up to 25 years
Some of the most useful cancer research doesn't come from a single dramatic breakthrough. It comes from watching patiently, for years, and noticing a pattern nobody had the data to see before. That's essentially what happened here. Researchers at the Wellcome Sanger Institute followed patients with chronic blood cancers for as long as 25 years and found that the genetic path toward disease progression may be set in motion long before anyone notices symptoms.
The study, published in the journal Cancer Discovery, focused on a group of blood cancers called myeloproliferative neoplasms, or MPNs. It's specific, technical research, but the implications are worth understanding in plain terms.
MPNs are a group of rare, long-term blood cancers that start in the bone marrow, where blood cells are made. In people with MPNs, the bone marrow produces certain blood cells in an uncontrolled way. There's a fuller explanation of the different types, including chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis, in this guide to myeloproliferative disorders.
Around 40,000 people in the UK live with MPNs, with roughly 4,000 new diagnoses each year, and these cancers typically progress slowly, sometimes over decades. Most cases are linked to mutations in one of three genes: JAK2, CALR, or MPL. But about 10 percent of patients don't have any of these known mutations, which creates a genuine diagnostic puzzle doctors have struggled with for years.
The team combined whole-genome sequencing with detailed clinical records covering nearly 8,000 blood test results, treatment histories, and disease data, drawn from 30 patients followed at Cambridge University Hospitals NHS Foundation Trust. More than 450 blood and bone marrow samples were analyzed through repeated genetic testing, some spanning a quarter century of routine care.
Using DNA from blood cells, the researchers built what they call genetic "family trees," tracing the ancestry of cancer clones, groups of genetically identical cells, back to their earliest origins. This let them watch, retrospectively, how each patient's disease actually evolved at the genetic level over time, not just how it looked clinically at any given visit.
Here's the central finding. Patients whose MPNs stayed clinically stable for years tended to have blood cell populations that were genetically "steady," picking up few or no new mutations over time. Patients whose disease eventually progressed to something more serious, leukemia or myelofibrosis (scarring of the bone marrow), showed new DNA changes accumulating well before their symptoms or standard blood tests reflected that shift.
In clinical practice, this is often the hardest conversation to have honestly with a patient: not being able to say with confidence whether their currently stable disease will stay that way. This research suggests that answer may already be written into the genetics of their blood cells, years before it becomes clinically obvious, which is a genuinely different way of thinking about monitoring these cancers going forward.
The researchers also studied patients who lacked the common JAK2, CALR, or MPL mutations, roughly 200 blood cell genomes' worth of family trees. Instead of cancer-like genetic patterns, they found changes more consistent with ordinary aging of the blood system rather than true malignancy.
This challenges an assumption that's shaped diagnosis for a while: that anyone with certain unusual bone marrow features has a genuine blood cancer. Some patients currently placed in that category may actually have biology that looks meaningfully different from real MPNs. The findings support newly published British Society for Haematology guidelines, which now recommend describing some of these patients as having thrombocytosis (a high platelet count) without JAK2, CALR, or MPL mutations, rather than immediately diagnosing blood cancer. That distinction matters, since as the researchers note, some patients in this uncertain category have received cancer treatment, including chemotherapy, without definitive genetic evidence they actually had a blood cancer to begin with.
The researchers frame this as a step toward more routine genomic monitoring in blood cancer care; using regular genetic testing to distinguish stable disease from disease likely to progress, refine uncertain diagnoses, and eventually flag high-risk patients years ahead of clinical decline. That could mean earlier intervention for people whose disease is heading toward progression, while sparing others unnecessary treatment for something that may not be true cancer at all.
None of this is available as a routine clinical test yet. This is discovery research, built on long-term data from a relatively small group of patients, and moving from "we found this pattern" to "here's a validated clinical test" takes real time and further study. Diagnosis and monitoring for MPNs and related blood cancers currently still rely on standard blood counts, bone marrow evaluation, and, when needed, supportive treatments such as blood transfusions for managing symptoms.
If you or someone you know is living with an MPN or a similar chronic blood cancer, this research doesn't change current monitoring or treatment. What it does offer is a genuinely hopeful sign that better, earlier answers about disease trajectory may be coming. Questions about individual risk, monitoring frequency, or genetic testing belong with a hematologist familiar with the specific diagnosis, not with headlines about a single study.
Understanding Myeloproliferative Disorders: Causes, Symptoms, and Treatment
Chemotherapy Explained: Understanding This Vital Cancer Treatment
Can an MRI Detect Cancer? Understanding Its Role in Diagnosis
Understanding Bone Cancer: Symptoms, Causes, and When to Seek Help
Visit Hospital
Near You
Find verified endocrinologists in Lucknow on DOCTAR. Compare experience, ratings, consultation fees and hospital locations, then book an appointment online.
August 22, 2026
Hormonal problems can affect weight, blood sugar, periods, energy levels, growth and several other parts of health. A hormone specialist, usually an endocrinologist, evaluates conditions involving the body's hormone-producing glands.
August 22, 2026
Find and book verified family doctors (general physicians) in Kolkata. Compare 327 doctors by fees (₹200–₹1,500), experience, ratings and hospital affiliation. Same-day appointments available with 316 doctors. Consultations in English, Hindi and Bengali.
August 22, 2026